[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360140-105":59,"doc-detail-360140-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-ehmt2-overcomes-5-fluorouracil-resistance-in-colorectal-cancer-modulating-cell-cycle-and-apoptosis","Targeting EHMT2 overcomes 5-fluorouracil resistance in colorectal cancer - modulating cell cycle and apoptosis","","5-Fluorouracil (5-FU) is a first-line treatment for colorectal cancer (CRC), but acquired resistance limits long-term benefit and key epigenetic drivers remain unclear. This study shows EHMT2 is upregulated in CRC patients with poor 5-FU responses, correlating with worse overall survival. In 5-FU resistant cell models, EHMT2 knockdown restores drug sensitivity by activating the EHMT2-PPM1B axis, causing G1 arrest and apoptosis, and suppressing growth in vivo and in patient-derived organoids.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-ehmt2-overcomes-5-fluorouracil-resistance-in-colorectal-cancer-modulating-cell-cycle-and-apoptosis/360140/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-ehmt2-overcomes-5-fluorouracil-resistance-in-colorectal-cancer-modulating-cell-cycle-and-apoptosis/360140.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How is 5-fluorouracil used to treat colorectal cancer, and what limits its effectiveness?","Question",{"text":113,"@type":114},"5-FU is a widely used cornerstone of combination chemotherapy for CRC. Its long-term clinical efficacy is limited by intrinsic or acquired chemoresistance, which occurs in up to 90% of metastatic cancer patients.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What relationship does the study identify between EHMT2 and 5-FU response in CRC patients?",{"text":118,"@type":114},"EHMT2 is significantly upregulated in CRC patients with poor responses to 5-FU. Higher EHMT2 levels correlate with lower overall survival.",{"name":120,"@type":111,"acceptedAnswer":121},"How does targeting EHMT2 restore sensitivity to 5-FU in resistant CRC models?",{"text":122,"@type":114},"EHMT2 knockdown restores 5-FU sensitivity by upregulating PPM1B, disrupting the EHMT2-PPM1B axis to induce G1 phase cell cycle arrest and trigger apoptosis in 5-FU resistant cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360140,1790192802,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nTargeting EHMT2 overcomes 5-ﬂuorouracil resistance in colorectal cancer by modulating cell cycle and apoptosis  \nIn Hwan Tae1, Yunsang Kang 1,2, Jinkwon Lee1, Jeong Min Lee1,2, Jinsan Kim1,2, Su-gi Lee1, Kunhyang Park1, Tae Young Ryu1, Kwangho Kim1, Gyeonghwa Kim 3, Taesang Son1,2, Hye Won Lee4, Solbi Kim5, Hyo Jin Lee5, Cho-Rok Jung1,2, Jung Hwa Lim1,2, Moo-Seung Lee 1,2, Keun Hur3 ✉ , Tae-Su Han1,2,6 ✉ , Dae-Soo Kim1,2 ✉ , Mi-Young Son1,2,6 ✉ and Hyun-Soo Cho 1,2,6,7 ✉  \n|  |  |  |\n| --- | --- | --- |\n|  | 5-Fluorouracil (5-FU) is a ﬁrst-line chemotherapy commonly used to treat colorectal cancer (CRC) . However, the development of acquired resistance to 5-FU remains a signiﬁcant clinical challenge, and the underlying epigenetic mechanisms are not fully understood. In this study, we demonstrate that euchromatic histone lysine methyltransferase 2 (EHMT2) is signiﬁcantly upregulated in CRC patients with poor responses to 5-FU, directly correlating with lower overall survival rates. Using established 5-FU resistant (5-FUR) HCT116 and HT29 cell lines, RNA-sequencing conﬁrmed robust EHMT2 overexpression compared with wild-type cells. Mechanistically, siRNA-mediated knockdown of EHMT2 restored 5-FU sensitivity by upregulating protein phosphatase 1B (PPM1B), a key downstream target. This EHMT2-PPM1B axis disruption effectively induced G1 phase cell cycle arrest and triggered apoptosis in 5-FUR cells, fundamentally impairing their proliferation. Furthermore, we validated the therapeutic potential of targeting this pathway using in vivo and ex vivo models. Combination treatment with 5-FU and the speciﬁc pharmacological EHMT2 inhibitor (BIX-01294) synergistically suppressed tumor growth in a 5-FUR cell-derived xenograft mouse model. Importantly, these therapeutic effects were faithfully recapitulated in 5-FUR patient-derived colorectal cancer organoid (PDO) models. Together, our ﬁndings elucidate a critical epigenetic mechanism where EHMT2 promotes 5-FU drug resistance. Targeting EHMT2 represents a promising |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| and translatable therapeutic strategy for overcoming chemoresistance and improving clinical outcomes in CRC patients. |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:184 ; [https://doi.org/10.1038/s41392-026-02692-7](https://doi.org/10.1038/s41392-026-02692-7) |  |\n|  |  |  |\n\nINTRODUCTION  \nColorectal cancer (CRC) remains the third most common cancer worldwide, representing a major public health challenge due to its high incidence and mortality rates1. Although signiﬁcant progress has been made in the development of new cancer treatments, including targeted therapies and immunotherapies, the pyrimidine analogue 5-ﬂuorouracil (5-FU) continues to be among the most effective and commonly used drugs for treating CRC and remains a cornerstone of standard combination chemotherapy regimens2. Additionally, the clinical utility of 5-FU extends far beyond colorectal tumors; it is widely used to treat various malignancies, including breast cancer, pancreatic cancer, skin cancer, gastric cancer, esophageal cancer, and head and neck cancer3,4. The potent anticancer efﬁcacy of 5-FU is primarily attributed to its ability to misincorporate into RNA and DNA and inhibit nucleotide synthesis. This mechanism ultimately serves to induce severe DNA damage, which leads to robust cell cycle arrest and the induction of apoptosis in rapidly dividing tumor cells5.  \nDespite the foundational role of 5-FU in oncology, its long-term clinical efﬁcacy is frequently compromised by the development of chemoresistance in cancer cells6,7. This resistance is a primary driver of low 5-year survival rates among advanced CRC patients, with therapeutic failure attributed ","cbCaiqMLTNEHkB5B","https://ap.wps.com/l/cbCaiqMLTNEHkB5B","pdf",8065760,14,"English","# Introduction\n## 5-Fluorouracil as a cornerstone therapy for CRC\n## Chemoresistance as a major barrier to long-term efficacy\n## Epigenetic dysregulation and rationale for epigenetic drug combinations\n## EHMT2 (G9a) as a key epigenetic target in CRC","[{\"question\":\"How is 5-fluorouracil used to treat colorectal cancer, and what limits its effectiveness?\",\"answer\":\"5-FU is a widely used cornerstone of combination chemotherapy for CRC. Its long-term clinical efficacy is limited by intrinsic or acquired chemoresistance, which occurs in up to 90% of metastatic cancer patients.\"},{\"question\":\"What relationship does the study identify between EHMT2 and 5-FU response in CRC patients?\",\"answer\":\"EHMT2 is significantly upregulated in CRC patients with poor responses to 5-FU. Higher EHMT2 levels correlate with lower overall survival.\"},{\"question\":\"How does targeting EHMT2 restore sensitivity to 5-FU in resistant CRC models?\",\"answer\":\"EHMT2 knockdown restores 5-FU sensitivity by upregulating PPM1B, disrupting the EHMT2-PPM1B axis to induce G1 phase cell cycle arrest and trigger apoptosis in 5-FU resistant cells.\"}]","Targeting EHMT2 overcomes 5-fluorouracil resistance in colorectal cancer - modulating cell cycle and apoptosis | PDF",1790138863,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e58c0128da21672700bc2140b29d95ab.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8d463fc3260e60ffa9993dfa06cd891.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2a93df099e09f58847eeda3bae1df32.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49da665fac6d876bff78a7298d589ffc.webp",980,1301]